Welcome to Shuangcheng Pharma
Founded in 2000, Hainan Shuangcheng Pharmaceuticals Co., Ltd (HNSP) is a publicly-traded company and engaged in development, manufacturing and marketing of both APIs and drug products. Having excellent know-how in peptide chemistry, HNSP is a leader in the field of peptide manufacture, with current U.S. FDA and AIFA (Italian Medicines Agency) approved production.
The company is headquartered near Haikou airport on Hainan Island, China with R&D and manufacturing facilities at the Haikou site, and is building new facilities in Ningbo, about 1.5 hours’ drive from Shanghai’s Pudong Airport (PVG). HNSP also has a subsidiary company in Italy.
HNSP is rapidly expanding in China and elsewhere around the world, and is presently seekingcollaborations and partnershipswith pharmaceutical companies in the U.S., Europe and other regions.
- Memantine Hydrochloride Tablets Receives US FDA MA approval2020-04-28
- Ningbo Shuangcheng Passes U.S. FDA Inspection2020-04-28
- Hainan Shuangcheng Passes U.S. FDA Inspection2020-04-28
- Bivalirudin for Injection Receives U.S. FDA Final Approval2020-04-28
- Shuangcheng Donates Medical Products to Support Fighting of COVID-192020-04-28
- Bivalirudin for Injection First Launched in U.S.2020-03-08
- Pregabalin Capsule ANDA Approved by U.S. FDA2019-10-08
- Hainan Shuangcheng Passes U.S. FDA Inspection2019-07-01
- Eptifibatide DMF Passes U.S. FDA Review2017-11-02